ProQR Historical Balance Sheet

PRQR Stock

USD 3.54 0.08 2.21%

Trend analysis of ProQR Therapeutics BV balance sheet accounts such as Total Stockholder Equity of 69.4 M, Other Liab of 80.9 M, Accounts Payable of 1.6 M or Cash of 92.9 M provides information on ProQR Therapeutics' total assets, liabilities, and equity, which is the actual value of ProQR Therapeutics to its prevalent stockholders. By breaking down trends over time using ProQR Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ProQR Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ProQR Therapeutics is a good buy for the upcoming year.

ProQR Therapeutics Inventory

0.95

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

About ProQR Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of ProQR Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. ProQR Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ProQR Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ProQR currently owns. An asset can also be divided into two categories, current and non-current.

ProQR Therapeutics Balance Sheet Chart

At this time, ProQR Therapeutics' Total Liabilities is relatively stable compared to the past year. As of 11/26/2024, Common Stock is likely to grow to about 4.1 M, while Short and Long Term Debt Total is likely to drop slightly above 18.5 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of ProQR Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ProQR Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on ProQR Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ProQR Therapeutics BV are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from ProQR Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into ProQR Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	60.4M	22.0M	19.7M	18.5M
Total Assets	209.6M	171.3M	138.0M	108.6M

Short Long Term Debt Total Total Assets

ProQR Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Property Plant And Equipment Gross
Total Assets		0.78	0.89	0.71	0.84	0.49	-0.9	-0.78	0.27	0.96	0.72	0.68	0.96	0.38	0.86	0.81	0.76	0.68	0.92	0.77	1.0	0.81	0.84	0.7	0.41	0.68
Short Long Term Debt Total	0.78		0.85	0.62	0.57	0.3	-0.58	-0.7	-0.1	0.76	0.75	0.9	0.76	0.13	0.73	0.73	0.68	0.47	0.77	0.68	0.75	0.66	0.5	0.74	0.27	0.65
Other Current Liab	0.89	0.85		0.74	0.67	0.44	-0.74	-0.83	0.06	0.85	0.73	0.76	0.85	0.3	0.9	0.86	0.75	0.73	0.93	0.77	0.88	0.82	0.62	0.72	0.39	0.68
Total Current Liabilities	0.71	0.62	0.74		0.38	0.87	-0.65	-0.93	0.56	0.66	0.86	0.39	0.66	0.23	0.69	0.84	0.9	0.51	0.8	0.95	0.68	0.95	0.45	0.86	0.9	0.93
Total Stockholder Equity	0.84	0.57	0.67	0.38		0.1	-0.92	-0.42	0.24	0.91	0.34	0.61	0.91	0.09	0.66	0.41	0.35	0.55	0.63	0.36	0.87	0.52	0.97	0.33	0.11	0.27
Other Liab	0.49	0.3	0.44	0.87	0.1		-0.39	-0.84	0.61	0.35	0.78	-0.03	0.35	0.47	0.49	0.72	0.86	0.26	0.63	0.88	0.45	0.84	0.21	0.78	0.92	0.9
Net Debt	-0.9	-0.58	-0.74	-0.65	-0.92	-0.39		0.61	-0.48	-0.96	-0.49	-0.54	-0.96	-0.09	-0.73	-0.59	-0.54	-0.59	-0.75	-0.58	-0.92	-0.72	-0.96	-0.48	-0.45	-0.49
Retained Earnings	-0.78	-0.7	-0.83	-0.93	-0.42	-0.84	0.61		-0.36	-0.67	-0.92	-0.44	-0.67	-0.42	-0.85	-0.93	-0.93	-0.48	-0.92	-0.95	-0.74	-0.98	-0.44	-0.91	-0.75	-0.93
Accounts Payable	0.27	-0.1	0.06	0.56	0.24	0.61	-0.48	-0.36		0.32	0.31	-0.22	0.32	-0.08	0.21	0.28	0.32	0.07	0.24	0.4	0.28	0.49	0.43	0.31	0.73	0.42
Cash	0.96	0.76	0.85	0.66	0.91	0.35	-0.96	-0.67	0.32		0.6	0.73	1.0	0.13	0.82	0.7	0.61	0.63	0.84	0.64	0.97	0.73	0.92	0.59	0.37	0.56
Non Current Assets Total	0.72	0.75	0.73	0.86	0.34	0.78	-0.49	-0.92	0.31	0.6		0.51	0.6	0.36	0.73	0.86	0.92	0.34	0.82	0.92	0.66	0.88	0.37	1.0	0.68	0.96
Long Term Debt	0.68	0.9	0.76	0.39	0.61	-0.03	-0.54	-0.44	-0.22	0.73	0.51		0.73	-0.08	0.58	0.5	0.43	0.52	0.59	0.43	0.67	0.41	0.51	0.5	0.01	0.39
Cash And Short Term Investments	0.96	0.76	0.85	0.66	0.91	0.35	-0.96	-0.67	0.32	1.0	0.6	0.73		0.13	0.82	0.7	0.61	0.63	0.84	0.64	0.97	0.73	0.92	0.59	0.37	0.56
Net Receivables	0.38	0.13	0.3	0.23	0.09	0.47	-0.09	-0.42	-0.08	0.13	0.36	-0.08	0.13		0.31	0.45	0.57	0.4	0.43	0.48	0.37	0.36	0.05	0.35	0.1	0.4
Common Stock Total Equity	0.86	0.73	0.9	0.69	0.66	0.49	-0.73	-0.85	0.21	0.82	0.73	0.58	0.82	0.31		0.89	0.69	0.5	0.97	0.7	0.84	0.84	0.66	0.72	0.41	0.65
Common Stock Shares Outstanding	0.81	0.73	0.86	0.84	0.41	0.72	-0.59	-0.93	0.28	0.7	0.86	0.5	0.7	0.45	0.89		0.88	0.5	0.95	0.89	0.77	0.89	0.45	0.85	0.61	0.85
Non Current Liabilities Total	0.76	0.68	0.75	0.9	0.35	0.86	-0.54	-0.93	0.32	0.61	0.92	0.43	0.61	0.57	0.69	0.88		0.54	0.84	0.99	0.73	0.9	0.38	0.92	0.72	0.97
Other Current Assets	0.68	0.47	0.73	0.51	0.55	0.26	-0.59	-0.48	0.07	0.63	0.34	0.52	0.63	0.4	0.5	0.5	0.54		0.57	0.54	0.7	0.51	0.49	0.32	0.2	0.38
Other Stockholder Equity	0.92	0.77	0.93	0.8	0.63	0.63	-0.75	-0.92	0.24	0.84	0.82	0.59	0.84	0.43	0.97	0.95	0.84	0.57		0.84	0.89	0.91	0.64	0.81	0.52	0.78
Total Liab	0.77	0.68	0.77	0.95	0.36	0.88	-0.58	-0.95	0.4	0.64	0.92	0.43	0.64	0.48	0.7	0.89	0.99	0.54	0.84		0.73	0.94	0.4	0.92	0.79	0.98
Total Current Assets	1.0	0.75	0.88	0.68	0.87	0.45	-0.92	-0.74	0.28	0.97	0.66	0.67	0.97	0.37	0.84	0.77	0.73	0.7	0.89	0.73		0.79	0.87	0.65	0.38	0.63
Common Stock	0.81	0.66	0.82	0.95	0.52	0.84	-0.72	-0.98	0.49	0.73	0.88	0.41	0.73	0.36	0.84	0.89	0.9	0.51	0.91	0.94	0.79		0.56	0.87	0.8	0.91
Net Tangible Assets	0.84	0.5	0.62	0.45	0.97	0.21	-0.96	-0.44	0.43	0.92	0.37	0.51	0.92	0.05	0.66	0.45	0.38	0.49	0.64	0.4	0.87	0.56		0.36	0.25	0.32
Property Plant And Equipment Net	0.7	0.74	0.72	0.86	0.33	0.78	-0.48	-0.91	0.31	0.59	1.0	0.5	0.59	0.35	0.72	0.85	0.92	0.32	0.81	0.92	0.65	0.87	0.36		0.69	0.96
Current Deferred Revenue	0.41	0.27	0.39	0.9	0.11	0.92	-0.45	-0.75	0.73	0.37	0.68	0.01	0.37	0.1	0.41	0.61	0.72	0.2	0.52	0.79	0.38	0.8	0.25	0.69		0.82
Property Plant And Equipment Gross	0.68	0.65	0.68	0.93	0.27	0.9	-0.49	-0.93	0.42	0.56	0.96	0.39	0.56	0.4	0.65	0.85	0.97	0.38	0.78	0.98	0.63	0.91	0.32	0.96	0.82

Click cells to compare fundamentals

ProQR Therapeutics Account Relationship Matchups

ProQR Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	117.5M	98.7M	209.6M	171.3M	138.0M	108.6M
Short Long Term Debt Total	13.6M	34.3M	60.4M	22.0M	19.7M	18.5M
Other Current Liab	9.0M	7.0M	14.8M	10.1M	8.8M	6.9M
Total Current Liabilities	11.0M	10.3M	27.6M	21.1M	34.2M	35.9M
Total Stockholder Equity	94.3M	57.1M	113.8M	65.5M	41.4M	69.4M
Net Debt	(98.4M)	(41.6M)	(127.2M)	(72.8M)	(99.2M)	(104.2M)
Retained Earnings	(211.7M)	(257.7M)	(317.8M)	(380.7M)	(400.9M)	(380.8M)
Accounts Payable	445K	221K	191K	392K	1.5M	1.6M
Cash	112.0M	75.8M	187.5M	94.8M	118.9M	92.9M
Non Current Assets Total	2.9M	18.7M	18.1M	16.9M	16.9M	17.8M
Long Term Debt	12.7M	16.2M	39.3M	4.3M	4.3M	4.1M
Cash And Short Term Investments	112.0M	75.8M	187.5M	94.8M	118.9M	92.9M
Net Receivables	850K	421K	555K	57.2M	1.3M	1.2M
Common Stock Total Equity	1.5M	1.7M	2.2M	2.2M	2.5M	1.3M
Common Stock Shares Outstanding	41.0M	50.1M	64.2M	71.6M	81.0M	41.6M
Liabilities And Stockholders Equity	117.5M	98.7M	209.6M	171.3M	138.0M	108.6M
Non Current Liabilities Total	12.7M	31.9M	68.8M	85.1M	62.3M	65.4M
Other Current Assets	1.5M	(800K)	3.1M	2.4M	793K	1.2M
Other Stockholder Equity	303.8M	288.8M	398.3M	412.5M	412.9M	236.7M
Total Liab	23.7M	42.2M	96.4M	106.2M	96.5M	101.3M
Total Current Assets	114.7M	80.0M	191.5M	154.5M	121.1M	100.7M
Common Stock	2.2M	2.2M	3.0M	3.4M	3.9M	4.1M
Net Tangible Assets	94.3M	57.1M	113.8M	65.5M	75.3M	82.9M
Property Plant And Equipment Net	2.4M	18.6M	17.5M	16.2M	16.9M	17.8M
Current Deferred Revenue	711K	700K	5.1M	5.8M	20.6M	21.6M
Property Plant And Equipment Gross	3.8M	18.6M	27.8M	29.1M	32.1M	33.7M
Short Long Term Debt	343K	1.1M	4.8M	2.5M	2.3M	2.1M
Accumulated Other Comprehensive Income	151K	(189K)	30.3M	30.3M	26.0M	27.3M
Short Term Debt	851K	2.4M	6.3M	3.9M	1.6M	2.0M
Property Plant Equipment	2.4M	18.6M	17.5M	16.2M	18.7M	19.6M
Capital Lease Obligations	508K	17.0M	16.3M	15.2M	15.4M	16.2M
Inventory	340K	379K	266.5K	6.9K	1.0	0.95
Net Invested Capital	107.4M	74.4M	157.9M	72.3M	45.7M	69.3M
Net Working Capital	103.7M	69.7M	163.9M	133.3M	86.8M	110.0M

Pair Trading with ProQR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against ProQR Stock

0.84	MTEM	Molecular Templates	Pair Corr
0.83	ME	23Andme Holding	Pair Corr
0.83	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.8	TPST	Tempest Therapeutics	Pair Corr
0.78	AGL	agilon health Buyout Trend	Pair Corr

The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.

The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ProQR Stock Analysis

When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ProQR Historical Balance Sheet

ProQR Therapeutics Inventory

0.95

About ProQR Balance Sheet Analysis

ProQR Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

ProQR Therapeutics balance sheet Correlations

ProQR Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ProQR Therapeutics balance sheet Accounts

Pair Trading with ProQR Therapeutics

Moving against ProQR Stock

Additional Tools for ProQR Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Net	+ 1.0	Non Current Assets Total
Total Liab	+ 0.99	Non Current Liabilities Total
Property Plant And Equipment Gross	+ 0.98	Total Liab
Net Tangible Assets	+ 0.97	Total Stockholder Equity

Common Stock	- 0.98	Retained Earnings
Net Tangible Assets	- 0.96	Net Debt
Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.96	Net Debt
Total Liab	- 0.95	Retained Earnings
Property Plant And Equipment Gross	- 0.93	Retained Earnings